Anti-LINGO-1

Anti-LINGO-1 is a myelin repair treatment being developed by Biogen.

Current phase of trial: phase 2

Type of MS: relapsing MS.

How does anti-LINGO-1 work?

LINGO is a protein found in nerve cells and the cells that make myelin. Blocking the activity of this protein with anti-LINGO-1 has been shown to result in myelin repair in animals with an MS-like condition.

Back to top

How is anti-LINGO-1 taken?

Anti-LINGO-1 is an intravenous infusion.

Back to top

Latest Research

SYNERGY trial

This phase 2 trial tested the safety and benefits of anti-LINGO-1 in relapsing MS. In June 2016 Biogen reported that anti-LINGO-1 had failed to improve measures of physical and cognitive function, or disability.

This trial involved 416 people who took different doses of anti-LINGO-1, or a placebo, once every 4 weeks for 72 weeks on top of weekly beta-interferon injections.

RENEW trial - optic neuritis

In this phase 2 trial anti-LINGO-1 improved signalling along the optic nerve by 41% compared with placebo. The trial involved 82 people who had experienced a first episode of acute optic neuritis. They took either six doses of anti-LINGO-1  or a placebo infusion over six months.Results were published in March 2017.

What are the side effects of anti-LINGO-1?

Some adverse effects of MS were reported in the RENEW trial: two people experienced hypersensitivity reactions to the infusion itself, while one person had an increase in liver enzymes (which was resolved by discontinuing the treatment).

Back to top

How does anti-LINGO-1 compare with current therapies?

Anti-LINGO-1 hasn’t yet been directly compared with other treatments for MS, so it isn't possible to draw conclusions about its relative effectiveness at this time.

Back to top

When is anti-LINGO-1 likely to become available?

In June 2016 Biogen reported that anti-LINGO-1 didn't improve measures of physical and cognitive function or disability in relapsing MS. We don't yet know what the next steps for anti-LINGO-1 will be.

Back to top

Page tagged with:

What's new?